Drug Interactions with Herbal Medicines

被引:0
作者
Shaojun Shi
Ulrich Klotz
机构
[1] Huazhong University of Science and Technology,Department of Pharmacy, Union Hospital, Tongji Medical College
[2] Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology,undefined
[3] University of Tuebingen,undefined
来源
Clinical Pharmacokinetics | 2012年 / 51卷
关键词
Berberine; Ginsenosides; Silymarin; Hypericin; Fexofenadine;
D O I
暂无
中图分类号
学科分类号
摘要
In recent years, the issue of herbal medicine-drug interactions has generated significant concern. Such interactions can increase the risk for an individual patient, especially with regard to drugs with a narrow therapeutic index (e.g. warfarin, ciclosporin and digoxin). The present article summarizes herbal medicine-drug interactions involving mainly inhibition or induction of cytochrome P450 enzymes and/or drug transporters. An increasing number of in vitro and animal studies, case reports and clinical trials evaluating such interactions have been reported, and the majority of the interactions may be difficult to predict. Potential pharmacodynamic and/or pharmacokinetic interactions of commonly used herbal medicines (black cohosh, garlic, Ginkgo, goldenseal, kava, milk thistle, Panax ginseng, Panax quinquefolius, saw palmetto and St John’s wort) with conventional drugs are presented, and sometimes the results are contradictory. Clinical implications of herbal medicine-drug interactions depend on a variety of factors, such as the co-administered drugs, the patient characteristics, the origin of the herbal medicines, the composition of their constituents and the applied dosage regimens. To optimize the use of herbal medicines, further controlled studies are urgently needed to explore their potential for interactions with conventional drugs and to delineate the underlying mechanisms.
引用
收藏
页码:77 / 104
页数:27
相关论文
共 50 条
  • [21] Recent advances in the compound-oriented and pattern-oriented approaches to the quality control of herbal medicines
    Zeng Z.
    Chau F.-T.
    Chan H.-Y.
    Cheung C.-Y.
    Lau T.-Y.
    Wei S.
    Mok D.K.-W.
    Chan C.-O.
    Liang Y.
    Chinese Medicine, 3 (1)
  • [22] Drug Interactions with St John’s WortMechanisms and Clinical Implications
    Marcus Mannel
    Drug Safety, 2004, 27 : 773 - 797
  • [23] Chinese herbal medicines for mild cognitive impairment A protocol for meta-analysis and trial sequential analysis
    Gu, Si-Chun
    Zhang, Li-Min
    Wang, Chun-Xu
    Qu, Yan-Jie
    Ma, Jing-Yi
    Zhen, Rong-Rong
    Gu, Chao
    Yuan, Can-Xing
    MEDICINE, 2021, 100 (39) : E27323
  • [24] Transporter-mediated drug-drug interactions
    Mueller, Fabian
    Fromm, Martin F.
    PHARMACOGENOMICS, 2011, 12 (07) : 1017 - 1037
  • [25] Metabolism, Transport and Drug-Drug Interactions of Silymarin
    Xie, Ying
    Zhang, Dingqi
    Zhang, Jin
    Yuan, Jialu
    MOLECULES, 2019, 24 (20):
  • [26] Drug-drug interactions of silymarin on the perspective of pharmacokinetics
    Wu, Jhy-Wen
    Lin, Lie-Chwen
    Tsai, Tung-Hu
    JOURNAL OF ETHNOPHARMACOLOGY, 2009, 121 (02) : 185 - 193
  • [27] Nanotechnology-based Herbal Drug Formulation in the Treatment of Diabetes Mellitus
    Bhadouria, Namrata
    Alam, Aftab
    Kaur, Awaneet
    CURRENT DIABETES REVIEWS, 2025, 21 (01) : e310124226554
  • [28] Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine
    Pradhan, S. C.
    Girish, C.
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2006, 124 (05) : 491 - 504
  • [29] Predicting Drug Candidate Victims of Drug-Drug Interactions, using Microdosing
    Croft, Marie
    Keely, Brendan
    Morris, Ian
    Tann, Lan
    Lappin, Graham
    CLINICAL PHARMACOKINETICS, 2012, 51 (04) : 237 - 246
  • [30] A proposed protocol based on integrative metabonomics analysis for the rapid detection and mechanistic understanding of sulfur fumigation of Chinese herbal medicines
    Dai Shengyun
    Wang Yuqi
    Wang Fei
    Mei Xiaodan
    Zhang Jiayu
    RSC ADVANCES, 2019, 9 (53) : 31150 - 31161